It seems like Medtronic is interested to
continue investing in aortic and peripheral vascular business, since it has
been among its fastest-growing divisions for the past five years. The company
has already disclosed an investment in Arsenal AAA, a subsidiary of Arsenal
Medical - which develops technology to avoid complications linked to
endovascular aneurysm repair (EVAR) procedures.
A few days after the announcement of
this investment, Medtronic revealed its acquisition of Aptus Endosystems –
maker of two FDA-cleared fastening devices and a steerable catheter for
delivery of peripheral vascular products, which Medtronic will distribute. This
statement was made during the Society for Vascular Surgery’s annual meeting.
In
a press release, the company said that these two investments were
“demonstrations of Medtronic’s’ commitment to leadership in the Aortic space.”
According to ReportsnReports.com, the market for aortic stent grafts is
expected to increase at a compound annual growth rate of 6.7% until 2020, when
it is expected to reach $1.9 billion. The market research company still states
“Despite the high product price, physicians still see a significant
benefit in providing endovascular options ahead of performing open surgery”.
References:
No comments:
Post a Comment